Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)